{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Baseline Positive and Post-baseline Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}],"title":"Baseline Negative and Post-baseline Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Baseline Positive and Post-baseline Transiently Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Baseline Negative and Post-baseline Transiently Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Baseline Positive and Post-baseline Persistently Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Baseline Negative and Post-baseline Persistently Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"groups":[{"description":"Participants received brentuximab vedotin 1.8 mg/kg, IV infusion, within 1 hour of completing treatment with other IV agents, i.e., cyclophosphamide 750 mg/m\\^2 and doxorubicin 50 mg/m\\^2, on Day 1 of each 21-day cycle, and prednisone tablets, 100 mg daily, orally, on Days 1 through 5, for up to 8 cycles (6 months) or until PD, unacceptable toxicity, whichever occurred first.","id":"OG000","title":"Brentuximab Vedotin + CHP"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The immunogenicity analysis set consisted of participants who received at least 1 dose of any of the study treatments and had an ADA status assessment at baseline and at least 1 postbaseline sample.","reportingStatus":"POSTED","timeFrame":"Pre-infusion on Day 1 of each cycle up to Cycle 8, and anytime within 30 days after last dose; each cycle = 21 days.","title":"Number of Participants Who Are Antidrug Antibodies (ADA) Negative, ADA Transiently and Persistently Positive","type":"SECONDARY","unitOfMeasure":"Participants"}